<![CDATA[Novo Nordisk A/S - Press Releases]]><![CDATA[43 research talents awarded scholarships to help secure Denmark’s future]]><![CDATA[Novo Nordisk establishes type 1 diabetes R&D center in Seattle]]><![CDATA[Data show that the combination insulin degludec/insulin aspart significantly reduced hypoglycaemia in type 1 and type 2 diabetes patients]]><![CDATA[Study in type 2 diabetes shows low rates of hypoglycaemia and significant improvements in blood glucose control with insulin analogue treatment]]><![CDATA[Novo Nordisk today announced the signing of its 5-year EUR 650,000,000 Revolving Credit Facility (the Facility).]]><![CDATA[Victoza® now available to people with type 2 diabetes in China]]><![CDATA[Positive opinion on the use of Levemir® (insulin detemir) in children with type 1 diabetes aged two to five years]]><![CDATA[Positive opinion on the usage of Levemir® (insulin detemir) as add-on therapy to Victoza® (liraglutide) in people with type 2 diabetes]]><![CDATA[Data show that ultra-long-acting insulin degludec can be flexibly dosed at any time of the day in people with type 2 diabetes]]><![CDATA[New data show people with type 2 diabetes experience greater improvements in glycaemic control when using Victoza® early in diabetes treatment]]><![CDATA[Novo Nordisk to build new corporate centre in Bagsværd, Denmark (VIDEO)]]><![CDATA[Novo Nordisk gains EU approval for FlexTouch® - the latest innovation within prefilled insulin pens.]]><![CDATA[Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control in patients with type 1 and type 2 diabetes]]><![CDATA[New data show Victoza(R) helped reduce blood sugar when patients with type 2 diabetes switched from sitagliptin or exenatide]]><![CDATA[Novo Nordisk upgraded to ‘A+’ by Standard & Poor’s]]><![CDATA[Novo Nordisk invests 1 billion Danish kroner in new factory in Denmark]]><![CDATA[One in five people with diabetes miss up to 15 working hours per month due to low blood sugar]]><![CDATA[New clinical trial data support the use of Levemir® in children aged two to five years]]><![CDATA[Novo Nordisk files annual report with the SEC]]><![CDATA[44 research talents get Novo scholarships to write their master theses]]>